Øyvind S Bruland

Title: Øyvind S Bruland: Innovator in Cancer Treatment

Introduction

Øyvind S Bruland is a prominent inventor based in Oslo, Norway. He has made significant contributions to the field of medicine, particularly in cancer treatment. With a total of 3 patents, his work focuses on innovative therapies that target specific cancer cells.

Latest Patents

One of Bruland's latest patents involves chimeric antigen receptors (CARs) that bind osteosarcoma. These CARs, when expressed on immune cells, can direct these cells to attack osteosarcoma cells. In a murine intraperitoneal model, T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies demonstrated a significant delay in tumor growth. The immune cells expressing these CARs showed a therapeutic effect, resulting in decreased tumor volume in a model simulating metastatic osteosarcoma. Importantly, stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, indicating their potential for safe treatment of osteosarcoma.

Another notable patent is related to radioimmunoconjugates that bind human CD37. This invention includes pharmaceutical compositions aimed at treating cancer, particularly B cell malignancies. The development of these radioimmunoconjugates represents a promising advancement in targeted cancer therapies.

Career Highlights

Bruland has worked with notable organizations such as Nordic Nanovector AS and Oslo Universitetssykehus HF. His experience in these institutions has contributed to his expertise in developing innovative cancer treatments.

Collaborations

Throughout his career, Øyvind S Bruland has collaborated with esteemed colleagues, including Roy Hartvig Larsen and Jostein Dahle. These partnerships have fostered a collaborative environment that enhances research and development in the field of oncology.

Conclusion

Øyvind S Bruland is a key figure in the advancement of cancer treatment through his innovative patents and collaborations. His work continues to pave the way for new therapeutic options in the fight against cancer.